Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma

Hematology

Volumn 12, Issue 3, 2007, Pages 235-239

  Wang, M ^a   Giralt, S ^a   Delasalle, K ^a   Handy, B ^a   Alexanian, R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Autologous stem cell transplantation; Bortezomib; Dexamethasone; Multiple myeloma; Thalidomide

Indexed keywords

ANTIBIOTIC AGENT; BENCE JONES PROTEIN; BETA 2 MICROGLOBULIN; BORTEZOMIB; DEXAMETHASONE; HEMOGLOBIN; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PARAPROTEIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE; WARFARIN;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CD34 SELECTION; CLINICAL ARTICLE; CONSTIPATION; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG POTENTIATION; DRY SKIN; EDEMA; FATIGUE; HUMAN; INDIGESTION; INFECTION; INSOMNIA; LUNG EMBOLISM; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STEM CELL MOBILIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; REMISSION INDUCTION; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 34250630470     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330701214236     Document Type: Article

References (29)

1. Dimopoulos, M., Zervas, K. and Kouvatseas, G. (2001) Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Onc, 12, pp. 991-995.
2. Anagnostopoulos, A., Weber, D. and Rankin, K. (2003) Thalidomide and dexamethasone for resistant multiple myeloma. Brit J Haemat, 121, pp. 768-771.
3. Rajkumar, S., Hayman, S. and Gertz, M. (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol, 20, pp. 4319-4323.
4. Weber, D., Rankin, K. and Gavino, M. (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol, 21, pp. 16-19.
5. Richardson, PG, Barlogie, B. and Berenson, J. (2003) A phase II study of bortezomib in relapsed, refractory myeloma. N Engl J Med, 348, pp. 2609-2617.
6. Richardson, P., Chanan-Khan, A. and Schlossman, R. (2004) Phase II trial of single agent bortezomib in patients with previously untreated multiple myeloma. Blood, 104, p. 104a.
7. Attal, M., Harousseau, J. and Stoppa, A. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Eng J Med, 335, pp. 91-97.
8. Child, J., Morgan, G. and Davies, F. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Eng J Med, 348, pp. 1875-1883.
9. Singhal, S., Powles, R. and Sirohi, B. (2002) Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and auto transplantation in myeloma. Bone Marrow Transplant, 30, pp. 673-679.
10. Alexanian, R., Weber, D. and Delasalle, K. (2004) Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant, 34, pp. 229-234.
11. Blade, J., Samson, D. and Reece, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Brit J Haemat, 102, pp. 1115-1123.
12. Bradwell, A., Carr-Smith, H. and Mead, G. (2003) Serum test for assessment of patients with Bence Jones myeloma. Lancet, 361, pp. 489-491.
13. Alexanian, R., Weber, D. and Giralt, S. (2001) Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant, 27, pp. 1037-1043.
14. Singhal, S., Mehta, J. and Desikan, R. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med, 341, pp. 1565-1571.
15. Rajkumar, S., Blood, E. and Vesole, D. (2004) A randomized phase II trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma. J Clin Oncol, 22, p. 560s.
16. Orlowski, RZ, Voorhees, PM and Garcia, RA (2005) Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood, 105, pp. 3058-3065.
17. Zangari, M., Barlogie, B. and Jacobson, J. (2003) VTD regimen effects a 57% PR rate among 56 patients with relapsing myeloma. Blood, 102, p. 236a.
18. Yang, H., Swift, R. and Sadler, K. (2003) A phase I/II trial of velcade and melphalan combination therapy for patients with relapsed or refractory multiple myeloma. Blood, 102, p. 235a.
19. Oakervee, H., Popat, R. and Curry, N. (2005) PAD combination therapy for previously untreated patients with multiple myeloma. Br J Haemat, 129, pp. 755-762.
20. Jagannath, S., Durie, B. and Wolf, J. (2005) Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Brit J Haemat, 129, pp. 776-783.
21. Hideshima, T., Bradner, JE and Wong, J. (2005) Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA, 102, pp. 8567-8572.
22. Mitsiades, N., Mitsiades, CS and Poulaki, V. (2002) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA, 99, pp. 14374-14379.
23. Turk, BD, Jiang, H. and Liu, JO (1996) Binding of thalidomide to alpha I-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci USA, 93, pp. 7552-7556.
24. Vacca, A., Scavelli, C. and Montefusco, V. (2005) Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol, 23, pp. 5334-5346.
25. Chauhan, D., Hideshima, T. and Pandey, P. (1997) Cytochrome c-dependent and -independent induction of apoptosis in multiple myeloma cells. J Biol Chemistry, 272, pp. 29995-29997.
26. Richardson, P., Schlossman, R. and Weller, E. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, pp. 3063-3067.
27. Dimopoulos, M., Weber, D. and Chen, C. (2005) Evaluating oral lenalidomide and dexamethasone versus placebo and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica, 90, p. 160.
28. Rajkumar, S., Hayman, S. and Lacy, M. (2005) Combination therapy with lenalidomide plus dexamethasone for newly diagnosed myeloma. Blood, 106, pp. 4050-4053.
29. Greipp, P., Miguel, J San and Durie, B. (2005) International staging system for multiple myeloma. J Clin Oncol, 23, pp. 3412-3420.